|
|
About Secondary Hyperparathyroidism (SHPT) in Chronic Kidney Disease (CKD)
When your kidneys aren’t healthy, they are less able to filter waste from your body. Unhealthy kidneys may be unable to maintain the right balance of fluids, minerals, and other substances in your body. An imbalance of minerals such as calcium and phosphorus can cause an overstimulation of the parathyroid gland. The parathyroid gland is part of the thyroid gland. It checks the levels of calcium and phosphorus in your body and sends out a hormone to control those levels. This hormone is called parathyroid hormone, or PTH. When your kidneys aren’t fully healthy, the parathyroid gland can send out too much PTH. So your body can get the wrong signals about maintaining the right balance of calcium and phosphorus. When you have too much PTH you have secondary hyperparathyroidism or SHPT. SHPT is a very common complication of Chronic Kidney Disease.
Over time, SHPT can cause serious problems with your bones and heart. It can result in too much calcium being taken from your bones, leaving them weak. SHPT can also contribute to calcium buildup in your heart or other areas where it doesn’t belong.
SHPT is commonly treated with a vitamin D medication.
hec_p_safety_info
Important Information About Hectorol®
Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 Chronic Kidney Disease (capsules) and in patients with Chronic Kidney Disease on dialysis (capsules and injection). Important Treatment Considerations
- Hectorol is contraindicated in patients with a tendency towards hypercalcemia or current evidence of vitamin D toxicity.
- Overdosage of any form of vitamin D is dangerous.
- Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis drugs.
- Chronic hypercalcemia can lead to generalized vascular and soft tissue calcification.
- Pharmacologic doses of vitamin D and its derivatives should be withheld during Hectorol treatment to avoid possible additive effects and hypercalcemia.
- Magnesium-containing antacids and Hectorol should not be administered concomitantly.
- Adverse effects of Hectorol treatment are: hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of iPTH.
- Adverse events reported by ≥ 5% of the Hectorol-treated predialysis patients included: infection, chest pain, constipation, dyspepsia, anemia, dehydration, depression, hypertonia, insomnia, paresthesia, increased cough, dyspnea, and rhinitis.
- Adverse events reported by ≥ 5% of the Hectorol-treated dialysis patients included: headache, malaise, bradycardia, nausea/vomiting, edema, dizziness, dyspnea, and pruritus.
- See
Hectorol Capsules Full Prescribing Information or Hectorol Injection Full Prescribing Information or call Genzyme Medical Information at 1-800-847-0069.
|
|
 |
|
|
|
| Contact |
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600
Email Us
|
 |
|
|
|
|
